Aug 24 (Reuters) - The European Commission on Thursday approved U.S. drugmaker Pfizer's vaccine for respiratory syncytial virus (RSV) to protect both babies and older adults in the European Union.

The EU on Friday authorized the sale of a vaccine to protect infants from respiratory syncytial virus (RSV), a disease that in worst cases can lead to pneumonia and bronchiolitis. The bloc-wide ...

Pfizer PFE announced that the European Commission has approved its new vaccine, Abrysvo, for the prevention of respiratory syncytial virus (RSV) in infants through immunization of their pregnant ...

The U.S. Centers for Disease Control and Prevention have recommended the first-ever vaccine designed to protect infants from ...

The advisory committee on immunizations for the Centers for DIsease Control and Prevention (CDC) voted to recommend an RSV ...

Women may soon have a vaccine they can take during a pregnancy to help protect their newborn from respiratory syncytial virus ...

Aug 24 (Reuters) - The European Commission on Thursday approved U.S. drugmaker Pfizer's (PFE.N) vaccine for respiratory syncytial virus (RSV) to protect both babies and older adults in the ...

The EU on Friday authorised the sale of a vaccine to protect infants from respiratory syncytial virus (RSV), a disease that in worst cases can lead to pneumonia and bronchiolitis. The bloc-wide ...

The EU on Friday authorised the sale of a vaccine to protect infants from respiratory syncytial virus (RSV), a disease that in worst cases can lead to pneumonia and bronchiolitis. The bloc-wide ...

Aug 24 (Reuters) - The European Commission on Thursday approved U.S. drugmaker Pfizer's PFE.N vaccine for respiratory syncytial virus (RSV) to protect both babies and older adults in the European ...

Brussels (AFP) – The EU on Friday authorised the sale of a vaccine to protect infants from respiratory syncytial virus (RSV), a disease that in worst cases can lead to pneumonia and bronchiolitis.